Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
CT, LBCL, large B-cell lymphoma, lisocabtagene maraleucel, axicabtagene ciloleucel, cost-effectiveness, CAR, chimeric antigen receptor T-cell therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要